{
    "clinical_study": {
        "@rank": "57101", 
        "arm_group": [
            {
                "arm_group_label": "HCP1201, Part 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2)."
            }, 
            {
                "arm_group_label": "Metformin and Rosuvastatin, Part1", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2)."
            }, 
            {
                "arm_group_label": "HCP1201, Part 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2)."
            }, 
            {
                "arm_group_label": "Metformin and Rosuvastatin, Part 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2)."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the pharmacokinetic characteristics between HCP1201 tablet 500/10 mg and\n      co-administration of metformin 500 mg plus rosuvastatin 10 mg under fasted and fed state,\n      respectively."
        }, 
        "brief_title": "Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After\n      the Administration of HCP1201 Tablet 500/10 mg and Coadministration of Metformin SR 500 mg\n      and Rosuvastatin 10 mg in Healthy Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteer, age 20~55 years\n\n          -  The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2\n\n          -  Subject who has the ability to comprehend the study objectives, contents and the\n             property of the study drug before participating in the trial.\n\n        Exclusion Criteria:\n\n          -  Presence of medical history or a concurrent disease that may interfere with treatment\n             and safety assessment or completion of this clinical study\n\n          -  History of relevant drug allergies or clinically significant hypersensitivity\n             reaction."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011633", 
            "org_study_id": "HM-MERO-105"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HCP1201, Part 1", 
                    "HCP1201, Part 2"
                ], 
                "description": "500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.", 
                "intervention_name": "HCP1201 500/10mg", 
                "intervention_type": "Drug", 
                "other_name": "HCP1201 500/10mg"
            }, 
            {
                "arm_group_label": [
                    "Metformin and Rosuvastatin, Part1", 
                    "Metformin and Rosuvastatin, Part 2"
                ], 
                "description": "Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.", 
                "intervention_name": "Metformin SR 500mg", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage SR 500 mg"
            }, 
            {
                "arm_group_label": "Metformin and Rosuvastatin, Part1", 
                "description": "Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.", 
                "intervention_name": "Rosuvastatin 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Crestor 10mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 500/10 mg and Coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Wooseong Huh, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "metformin, rosuvastatin Cmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }, 
            {
                "measure": "metformin, rosuvastatin AUClast", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011633"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Metformin, rosuvastatin Tmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }, 
            {
                "measure": "Metformin, rosuvastatin T1/2", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }, 
            {
                "measure": "Metformin, rosuvastatin AUCinf", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}